MIMETAS develops scalable organ-on-a-chip platforms and human tissue models that allow researchers to study disease mechanisms and compound responses in perfused, biologically relevant systems. Its OrganoPlate® platform combines a standard microtiter-plate format with membrane-free microfluidic tissue cultures, supporting imaging, automated handling and higher-throughput research and development workflows. Bruker plans to combine these capabilities with its technologies in proteomics, metabolomics, NMR, preclinical imaging and spatial biology.

“Human physiology-relevant tissue and disease models are becoming increasingly important for understanding disease biology and evaluating therapeutic candidates,” said Frank H. Laukien, President and CEO of Bruker Corporation. “The unique MIMETAS organ-on-a-chip platforms complement Bruker’s capabilities in multiomics, spatial biology and preclinical imaging. We believe that humanized Microphysiological Systems, or NAMs, have a bright future, and will be increasingly adopted in drug discovery, development and preclinical testing.”

The MIMETAS portfolio includes the OrganoPlate platform for organ-on-a-chip research, OrganoReady® tissue and organoid products, supporting instruments and contract research services. The companies plan to develop integrated product and service workflows that connect these human model systems with Bruker technologies and services for molecular and cellular characterization.

A Senior Scientific Director at a global pharmaceutical company commented: “The OrganoReady Colon Organoid Model combined with the OrganoTEER® system has become fully integrated into our toxicity-testing workflow. The platform fits seamlessly into our routine screening and supports consistent, reproducible data generation.”

“Joining Bruker creates opportunities to scale our platforms and make advanced human tissue models available to more researchers worldwide,” said Paul Vulto and Jos Joore, co-founders and co-CEOs of MIMETAS. “By combining our OrganoPlate and OrganoReady solutions with Bruker’s molecular and cellular characterization technologies, we aim to offer more integrated workflows for disease research, compound evaluation and drug development.”

Bruker and MIMETAS serve pharmaceutical and biotechnology researchers with complementary technologies. The combination is expected to connect advanced human tissue models with molecular, cellular and spatial characterization, supporting evidence generation for disease research, drug-development decisions and AI foundation models.

Financial details of the transaction were not disclosed. MIMETAS will continue to operate under its established brand and management.